Selected Publications:
Bland P, et al. (2023), SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response, Nature Genetics, (8):1311-1323.
Reijns MAM, et al. (2022), Signatures of TOP1 transcription-associated mutagenesis in cancer and germline, Nature, 602(7898):623-631.
Kennedy E, et al. (2021), TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target, Blood, 137(22):3064-3078.
Kwok M, et al. (2020), Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL, Blood, 135(6):411-428.
Balmus G et al. (2019), ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks, Nat Commun, 10(1):87.
Zimmermann M, et al. (2018) CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions, Nature, 559(7713):285-289.
Pratt G, et al. (2018), A phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma, BJH, 182(3):429-433.
Agathanggelou A, et al. (2017). USP7 inhibition alters homologous recombination repair and targets CLL cells independent of ATM/p53 functional status, Blood, 130(2):156-166.
Kwok M, et al. (2016), ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells, Blood, 127(5):582-595.
View all publications in research portal